CAMBRIDGE, MA — Alkermes Inc. (NASDAQ: ALKS) today announced that it has made a $100 million
equity investment in Reliant Pharmaceuticals LLC in exchange for approximately 19% ownership of
the company. Alkermes’ investment was accompanied by a $50 million investment
by Pritzker family business interests and Bay City Capital, the major equity
owners of Reliant. Reliant Pharmaceuticals is a rapidly growing, privately held pharmaceutical
company marketing branded, patent-protected pharmaceutical products to
U.S.-based primary care and targeted specialty physicians.